Another double-blind randomized controlled trial revealed that administration of 200 mg/day of Eriomin for 12 weeks decreased hyperglycemia (6%), increased GLP-1 blood levels (22%) (p < 0.05), and altered microbiota composition in prediabetic patients compared with the results for the placebo group [108]. The gene discussed is GCG; the disease is Hyperglycemia.